BI opens up data files

Share this article:

Boehringer Ingelheim announced Monday that it will make clinical study data accessible once a drug has been approved or a drug development program has been terminated.

The company said in a statement Monday that researchers will be able to request de-identified patient data and will receive information if an independent third-party review panel approves the study proposal. BI will redact the information.

The data repository will go back to 1998.

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.